» Articles » PMID: 20381875

Handwriting Movement Kinematics for Quantifying Extrapyramidal Side Effects in Patients Treated with Atypical Antipsychotics

Overview
Journal Psychiatry Res
Specialty Psychiatry
Date 2010 Apr 13
PMID 20381875
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Ongoing monitoring of neuroleptic-induced extrapyramidal side effects (EPS) is important to maximize treatment outcome, improve medication adherence and reduce re-hospitalization. Traditional approaches for assessing EPS such as Parkinsonism, tardive akathisia, or dyskinesia rely upon clinical ratings. However, these observer-based EPS severity ratings can be unreliable and are subject to examiner bias. In contrast, quantitative instrumental methods are less subject to bias. Most instrumental methods have only limited clinical utility because of their complexity and costs. This paper describes an easy-to-use instrumental approach based on handwriting movements for quantifying EPS. Here, we present findings from psychiatric patients treated with atypical (second generation) antipsychotics. The handwriting task consisted of a sentence written several times within a 2 cm vertical boundary at a comfortable speed using an inkless pen and digitizing tablet. Kinematic variables including movement duration, peak vertical velocity and the number of acceleration peaks, and average normalized jerk (a measure of smoothness) for each up or down stroke and their submovements were analyzed. Results from 59 psychosis patients and 46 healthy comparison subjects revealed significant slowing and dysfluency in patients compared to controls. We observed differences across medications and daily dose. These findings support the ecological validity of handwriting movement analysis as an objective behavioral biomarker for quantifying the effects of antipsychotic medication and dose on the motor system.

Citing Articles

Handwriting Kinematics in Patients with Schizophrenia Treated with Long-Acting Injectable Atypical Antipsychotics: Results From the ALPINE Study.

Caligiuri M, Weiden P, Legedza A, Yagoda S, Claxton A Schizophr Bull Open. 2024; 3(1):sgac018.

PMID: 39144789 PMC: 11205961. DOI: 10.1093/schizbullopen/sgac018.


Examining Motor Anticipation in Handwriting as an Indicator of Motor Dysfunction in Schizophrenia.

Crespo Cobo Y, Kandel S, Soriano M, Iglesias-Parro S Front Psychol. 2022; 13:807935.

PMID: 35432092 PMC: 9012163. DOI: 10.3389/fpsyg.2022.807935.


An Instrumental Measure of Hand and Facial Movement Abnormalities in Patients With Schizophrenia.

Wang S, Ouyang W, Hsu H, Hsu L Front Psychiatry. 2022; 13:803661.

PMID: 35308887 PMC: 8931260. DOI: 10.3389/fpsyt.2022.803661.


The psychosis human connectome project: An overview.

Demro C, Mueller B, Kent J, Burton P, Olman C, Schallmo M Neuroimage. 2021; 241:118439.

PMID: 34339830 PMC: 8542422. DOI: 10.1016/j.neuroimage.2021.118439.


Sensorimotor and Activity Psychosis-Risk (SMAP-R) Scale: An Exploration of Scale Structure With Replication and Validation.

Damme K, Schiffman J, Ellman L, Mittal V Schizophr Bull. 2020; 47(2):332-343.

PMID: 33047134 PMC: 7965079. DOI: 10.1093/schbul/sbaa138.


References
1.
Chrzanowski W, Marcus R, Torbeyns A, Nyilas M, McQuade R . Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl). 2006; 189(2):259-66. DOI: 10.1007/s00213-006-0564-3. View

2.
Tandon R, Jibson M . Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry. 2002; 14(2):123-9. DOI: 10.1023/a:1016811222688. View

3.
Marder S, McQuade R, Stock E, Kaplita S, Marcus R, Safferman A . Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003; 61(2-3):123-36. DOI: 10.1016/s0920-9964(03)00050-1. View

4.
Weiden P . EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract. 2007; 13(1):13-24. DOI: 10.1097/00131746-200701000-00003. View

5.
Gerken A, WETZEL H, Benkert O . Extrapyramidal symptoms and their relationship to clinical efficacy under perphenazine treatment. A controlled prospective handwriting-test study in 22 acutely ill schizophrenic patients. Pharmacopsychiatry. 1991; 24(4):132-7. DOI: 10.1055/s-2007-1014456. View